ArticlePloS one2026
Exploring the role of the key gene TNFAIP3 between periodontitis and influenza A through bioinformatic analysis and molecular docking.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have hinted at a link between periodontitis (PD) and influenza A (IA). Therefore, this study aims to identify key genes common to both diseases by studying Porphyromonas gingivalis (P.gingivalis) and the H1N1 virus, the main pathogen of PD and IA, evaluating the promise of these genes as biomarkers, and providing future therapeutic strategies for both diseases. Our research employs a wide range of methods, including bioinformatics analysis, drug prediction and molecular docking. Ultimately, machine learning algorithms identified TNFAIP3 as a common key gene for PD and IA, and further identified five drugs: Vemurafenib, Metformin, Dexamethasone, Tretinoin and Imatinib with potential for combined treatment of PD and IA. Our study reveals the shared mechanism and immune profile of TNFAIP3 as a key gene in PD and IA, which lays a theoretical foundation for future targeted therapies based on the shared mechanism of the two diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.